Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

prnasiaSeptember 28, 2021

Tag: Innovent , AnHeart , Taletrectinib

PharmaSources Customer Service